Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Nippon Shinyaku to Concentrate Sales Force in Three Therapeutic Fields
June 11, 2014
- PII Study of Novel AD Treatment Begins in Japan: Fujifilm Holdings
June 11, 2014
- Novartis Pharma Collects Adverse Events of 10,000 Patients in Wake of Unreported ADRs in SIGN Trial
June 10, 2014
- Nippon Kayaku to Deploy RA Reps for Remicade Biosimilar
June 9, 2014
- April Ethical Drug Sales Down 3.5%, Hurt by Pullback from Pre-Tax Hike Demand: Crecon Report
June 9, 2014
- Results from PI/PII Studies of BBI608, BBI503 Presented at ASCO Annual Meeting: DSP
June 9, 2014
- AbbVie Can Achieve 100 Billion Yen Sales Target Ahead of Schedule: President
June 6, 2014
- Malignant STS Treatment Trabectedin Achieves Primary Endpoint in Domestic PII Clinical Trial: Taiho
June 6, 2014
- Nihon Chouzai to Provide Online Daily Pharmacy Prescription Trend Info.
June 6, 2014
- Combination Therapy of Avastin, Tarceva Significantly Prolongs PFS in PII Study: Roche
June 6, 2014
- Sales of 26 Pharma Companies Up 10.3% Driven by Strong Overseas Sales
June 5, 2014
- Astellas to Issue Monthly EPPV Reports on Suglat for One Year: Product Manager
June 5, 2014
- Sysmex Inostics, Merck Serono of Germany to Codevelop CoDx for Erbitux for Treatment of Colon Cancer
June 5, 2014
- Eisai’s Halaven Extends OS in Metastatic Breast Cancer Patients
June 4, 2014
- Taiho’s TS-1 Able to Prolong Life for Metastatic, Relapsed Breast Cancer Patients
June 4, 2014
- Shionogi Establishes Wholly Owned Subsidiary in Singapore as Foothold for Development and Marketing in ASEAN States
June 4, 2014
- Nexavar Fails to Show Efficacy in Adjuvant Therapy for Liver Cancer: Bayer Yakuhin
June 4, 2014
- Eisai’s Anticancer Agent Lenvatinib Significantly Extends PFS in PIII Study
June 3, 2014
- Teijin Ups FY2015 Japan Sales Target for Feburic to 20-Plus Billion Yen
June 3, 2014
- MTPC to Merge Its Subsidiary Benesis in October
June 3, 2014
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…